43 results on '"Hirayama, Fukushi"'
Search Results
2. Novel strategy to boost oral anticoagulant activity of blood coagulation enzyme inhibitors based on biotransformation into hydrophilic conjugates
3. Pharmacological profile of AS1670542, a novel orally-active human thrombopoietin receptor agonist
4. Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors
5. Design, synthesis and biological activity of selective and orally available TF/FVIIa complex inhibitors containing non-amidine P1 ligands
6. Potent and selective TF/FVIIa inhibitors containing a neutral P1 ligand
7. AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist
8. Synthesis and biological activity of novel 1,2-disubstituted benzene derivatives as factor Xa inhibitors
9. Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives
10. Synthesis and biological activity of novel 1,4-diazepane derivatives as factor Xa inhibitor with potent anticoagulant and antithrombotic activity
11. Design, synthesis and biological activity of YM-60828 derivatives. Part 2: potent and orally-bioavailable factor Xa inhibitors based on benzothiadiazine-4-one template
12. Design, synthesis and biological activity of YM-60828 derivatives: potent and orally-Bioavailable factor Xa inhibitors based on naphthoanilide and naphthalensulfonanilide templates
13. The Discovery of YM-60828: A Potent, Selective and Orally-Bioavailable Factor Xa Inhibitor
14. Discovery of N-[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (Darexaban, YM150) as a Potent and Orally Available Factor Xa Inhibitor
15. AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis
16. Effects of Direct Factor Xa Inhibitor, YM150, on Clot Formation and Clot Lysis In Vitro Compared with Other Anticoagulants.
17. Comparison of YM150, an Oral, Direct Factor Xa Inhibitor, with Other Antithrombotic Agents in Rodent Venous and Arterial Thrombosis Models.
18. One-Pot Synthetic Procedure for 2,2′-Disubstituted Biaryls via the Suzuki Coupling Reaction of Aryl Triflates in a Biphasic Solvent System.
19. One‐Pot Synthetic Procedure for2,2′‐Disubstituted Biaryls via the Suzuki Coupling Reaction of Aryl Triflates in a Biphasic Solvent System
20. Biochemical and Pharmacological Profiles of YM150, an Oral Direct Factor Xa Inhibitor.
21. YM477, a Novel Orally-Active Thrombopoietin Receptor Agonist.
22. An Easy to 7-Methyl-2-naphthalenecarbonitrile.
23. An Easy Access to 7-Methyl-2-naphthalenecarbonitrile
24. Antithrombotic effects of YM466, a synthesized direct inhibitor of factor Xa, in an arterio‐venous shunt thrombosis model in squirrel monkeys
25. ChemInform Abstract: The Discovery of YM‐60828: A Potent, Selective and Orally‐Bioavailable Factor Xa Inhibitor.
26. Research and Development of Novel Anti-thrombotic Agents. New anticoagulants.
27. Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time
28. Antithrombotic effects of YM-60828 in three thrombosis models in guinea pigs
29. Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats
30. Effect of a Synthetic Factor Xa Inhibitor, YM-60828, on Blood Vessel Patency in Combination with a Thrombolytic Agent and on Blood Loss from the Operation Site in a Rat Model of Arterial Thrombosis
31. Biochemical and Pharmacological Characterization of YM-60828, a Newly Synthesized and Orally Active Inhibitor of Human Factor Xa
32. Comparison of YM-60828, a Newly Synthesized factor Xa Inhibitor, and SC-54701A, a Selective GPIIb/IIIa Antagonist: Antithrombotic Activity in Three Thrombosis Models in Guinea Pigs
33. Comparative Studies of an Orally-active Factor Xa Inhibitor, YM-60828, with other Antithrombotic Agents in a Rat Model of Arterial Thrombosis
34. Antithrombotic effects of YM‐60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time
35. YM-60828, a novel factor Xa inhibitor: Separation of its antithrombotic effects from its prolongation of bleeding time
36. A new alkaloid antibiotic tetrazomine structure determination.
37. Comparative Studies of an Orally-active Factor Xa Inhibitor, YM-60828, with other Antithrombotic Agents in a Rat Model of Arterial Thrombosis
38. Effect of a Synthetic Factor Xa Inhibitor, YM-60828, on Blood Vessel Patency in Combination with a Thrombolytic Agent and on Blood Loss from the Operation Site in a Rat Model of Arterial Thrombosis
39. Biochemical and Pharmacological Characterization of YM-60828, a Newly Synthesized and Orally Active Inhibitor of Human Factor Xa
40. 4-Aminopyridine-2,3-dicarboxylic acid from Clitocybe acromelalga
41. Sulfated pentagalloyl glucose (Y-ART-3) inhibits HIV replication and cytopathic effects in vitro, and reduces HIV infection in hu-PBL-SCID mice
42. Effects of Direct Factor Xa Inhibitor, YM150, on Clot Formation and Clot Lysis In VitroCompared with Other Anticoagulants.
43. P-203 - Comparison of YM-60828, a Newly Synthesized factor Xa Inhibitor, and SC-54701A, a Selective GPIIb/IIIa Antagonist: Antithrombotic Activity in Three Thrombosis Models in Guinea Pigs
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.